TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01394809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motor cognitive therapies
Description: pre-test; 6 weeks intervention: week 1-3: 5 times per week 60 minutes a day. Week 4-6: 3 times per week 60 minutes a day; post-test; follow-up)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motor cognitive therapies
Description: pre-test; 6 weeks intervention: week 1-3: 5 times per week 60 minutes a day. Week 4-6: 3 times per week 60 minutes a day; post-test; follow-up)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: motor cognitive therapies
Description: pre-test; 6 weeks intervention: week 1-3: 5 times per week 60 minutes a day. Week 4-6: 3 times per week 60 minutes a day; post-test; follow-up)
Study: NCT06076343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT skills-training and Family Connections interventions
Description: DBT skills-training program includes four modules: 1. Mindufulness, 2. Distress Tolerance, 3. Emotion Regulation, 4. Interpersonal effectiveness.~FC program includes six modules: 1. Introduction, 2. Family Education, 3. Relationship Mindfulness Skills, 4. Family Environment Skills, 5. Validation Skills, 6. Problem Management Skills.
Study: NCT00742573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antidepressants through Texas Medication Algorithm (TMA)
Description: Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressants through Texas Medication Algorithm (TMA)
Description: Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Interpersonal Psychotherapy (IPT-B)
Description: IPT-B consists of twelve 50-minute sessions, divided into three phases, focusing on an interpersonal problem or problems.
Study: NCT03681730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
Study: NCT03378479

Intervention type: DRUG
Group type: OTHER
Intervention: SOC +Posaconazole 18 MG/ML (milligram/milliliter)
Description: .2\*300mg/d IV on day 1, followed by 1\*300mg/d IV from day 2 for 7 days (total 7 days)

Intervention type: OTHER
Group type: OTHER
Intervention: standard of care (SOC)
Description: treatment for influenza pneumonia at the investigators discretion
Study: NCT00609349

Intervention type: DEVICE
Group type: OTHER
Intervention: ETED, CPET, RHC
Description: exercise tricuspid echo doppler (ETED): allows the estimation of systolic pulmonary arterial pressure at exercise cardiopulmonary exercise test (CPET) allows to measures exercise capacity (peakVO2)~right heart catheterisation (RHC): is the gold standard for the measurement of pulmonary arterial pressure values
Study: NCT02998320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genvoya
Description: Oral use (one tablet each day); 150/150/200/10 mg; 28 days
Study: NCT03378479

Intervention type: OTHER
Group type: OTHER
Intervention: standard of care (SOC)
Description: treatment for influenza pneumonia at the investigators discretion
Study: NCT02860091

Intervention type: DRUG
Intervention: Ropivacaine infusion
Description: Delivered via paravertebral nerve block catheter.
Study: NCT03298087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical prostatectomy
Description: surgical removal of the prostate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy
Description: Highly targeted radiation
Study: NCT03968367

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic activated sperm sorting
Description: MACS is a technique which allows the spermatozoa with the best characteristics to be selected for use in assisted reproduction treatments. This technique removes apoptotic spermatozoa - those which will die without achieving fertilisation - and selects the healthy ones, thus increasing the possibility of pregnancy.
Study: NCT02545296

Intervention type: OTHER
Group type: OTHER
Intervention: In-vitro Diagnostics
Description: Ex-vivo performed diagnostic blood based test.
Study: NCT01737255

Intervention type: OTHER
Intervention: Psychological questionnaires
Description: All recruits will complete questionnaires at 6 time points to assess psychological impact

Intervention type: OTHER
Intervention: Psychological questionnaires
Description: All recruits will complete questionnaires at 6 time points to assess psychological impact
Study: NCT02179593

Intervention type: OTHER
Group type: OTHER
Intervention: 2-Segment SARPE
Description: Le Fort I osteotomy with oppening of the median palatal suture and SARPE.

Intervention type: OTHER
Group type: OTHER
Intervention: 3-Segment SARPE
Description: Le Fort I osteotomy with two parallel osteotomies symetrically positioned with reference to the median palatal suture and SARPE.
Study: NCT01830153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Study: NCT03495427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-DCFPyL Injection
Description: F-DCFPyL Injection is a radioactive diagnostic imaging agent indicated for imaging of patients with recurrent prostate cancer.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA PET
Description: PSMA PET imaging (for men with high GC \>0.45) will be done after 2 years post-treatment, then yearly up to 5 years.
Study: NCT04027465

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg allergy oral desensitization
Description: Subjects in the treatment will begin treatment by undergoing an egg oral challenge. This will confirm that the subject is still allergic to egg and establish the dose of egg the subject can tolerate. The last dose of egg tolerated during the challenge will serve as the first desensitization dose Subjects will then come to the research center every two weeks to receive their dose increases until they reach the maintenance dose of 300 mg. Subjects will then enter the maintenance phase for one year. During this period they will undergo another oral food challenge one month after attaining the maintenance dose
Study: NCT04636450

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotatory technique pulpectomy
Description: Primary mandibular molars treated with a rotatory technique pulpectomy and a K3 system or a Kedo-S system.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotatory technique pulpectomy
Description: Primary mandibular molars treated with a rotatory technique pulpectomy and a K3 system or a Kedo-S system.
Study: NCT03298087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Lowers serum testosterone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apalutamide
Description: antiandrogen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone
Description: Inhibits androgen synthesis
Study: NCT04636450

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual pulpectomy
Description: Primary mandibular molars treated with a manual pulpectomy and a K-file system or a Kedo-SH system.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual pulpectomy
Description: Primary mandibular molars treated with a manual pulpectomy and a K-file system or a Kedo-SH system.
Study: NCT05222360

Intervention type: OTHER
Intervention: Education
Description: 3 educational sessions about body image and nutrition
Study: NCT04931160

Intervention type: OTHER
Group type: OTHER
Intervention: Blood, fluid, sells and urine samples
Description: Blood, fluid, sells and urine samples will be collected.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood, fluid, sells and urine samples
Description: Blood, fluid, sells and urine samples will be collected.
Study: NCT04556734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Etrasimod 2 mg tablet by mouth, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Etrasimod 3 mg (1 mg and 2 mg tablets) by mouth, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Etrasimod matching placebo tablet by mouth, once daily
Study: NCT04208256

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Energy Stimulus
Description: Energy stimulus (energy surplus v. energy neutral) will be randomly assigned at the first brain imaging visit. At the second brain imaging visit, the participant will receive the alternate stimulus from what they received at the first brain imaging visit.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Energy Stimulus
Description: Energy stimulus (energy surplus v. energy neutral) will be randomly assigned at the first brain imaging visit. At the second brain imaging visit, the participant will receive the alternate stimulus from what they received at the first brain imaging visit.
Study: NCT02335372

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wide-Field White Light Imaging
Description: Initial wide-field white light images acquired of cervix in unpolarized and cross-polarized modes during cervical colposcopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetic Acid
Description: 3-6% acetic acid applied to cervix after wide-field while light imaging during colposcopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine Solution
Description: Topical application of 0.01% proflavine solution applied for 1 minute to cervix after sites for biopsy have been identified during colposcopy.
Study: NCT02594072

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic ablative radiotherapy
Description: Linac-based prostate stereotactic radiotherapy, using Volumetric Modulated Arc Therapy planning and delivery, with fiducial marker and cone-beam CT based image guidance.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: external beam radiation therapy
Description: Conventional intensity modulated radiotherapy, with fiducial marker or cone-beam CT based image guidance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoladex ®
Description: The preferred agent for the protocol is goserelin acetate (Zoladex ®) 3-month depot, but other LHRH agonists are permitted. The total duration of ADT will be 6 months for men with intermediate risk disease, and 18 months for those with high risk disease. ADT is to be initiated prior to the start of RT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoladex ®
Description: The preferred agent for the protocol is goserelin acetate (Zoladex ®) 3-month depot, but other LHRH agonists are permitted. The total duration of ADT will be 6 months for men with intermediate risk disease, and 18 months for those with high risk disease. ADT is to be initiated prior to the start of RT.
Study: NCT03070834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook 'Celect' retrievable inferior vena cava filter
Description: Cook 'Celect' device will be deployed If randomized to rIVCF insertion
Study: NCT03842280

Intervention type: DEVICE
Intervention: Diaphragm ultrasound assessment & Esophageal pressure measurement
Description: Diaphragm ultrasound assessment and/or Esophageal pressure measurement before, during and after spontaneous breathing trial
Study: NCT02220400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study: NCT03374956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine-Topiramate
Description: Extended Release at dose of 7.5/46 mg oral daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine-Topiramate
Description: Extended Release at dose of 7.5/46 mg oral daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: dose of 3 mg subcutaneous daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: dose of 3 mg subcutaneous daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone/bupropion
Description: Oral naltrexone extended-release/bupropion extended-release at dose of 32/360 mg oral daily (divided in 2 tables in morning and 2 tablets in evening)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone/bupropion
Description: Oral naltrexone extended-release/bupropion extended-release at dose of 32/360 mg oral daily (divided in 2 tables in morning and 2 tablets in evening)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine
Description: 15-37.5 mg oral daily
Study: NCT00752219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftazidime/NXL104 + metronidazole
Description: IV TID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meropenem
Description: IV TID
Study: NCT03847519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADXS-503
Description: A live attenuated Listeria monocytogenes (Lm)-based immunotherapy bioengineered to elicit T cell responses against shared tumor antigens commonly found in patients with squamous and non-squamous NSCLC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADXS-503
Description: A live attenuated Listeria monocytogenes (Lm)-based immunotherapy bioengineered to elicit T cell responses against shared tumor antigens commonly found in patients with squamous and non-squamous NSCLC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADXS-503
Description: A live attenuated Listeria monocytogenes (Lm)-based immunotherapy bioengineered to elicit T cell responses against shared tumor antigens commonly found in patients with squamous and non-squamous NSCLC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: a programmed death receptor-1 (PD-1)- blocking antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: a programmed death receptor-1 (PD-1)- blocking antibody.
Study: NCT01242085

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trumatch group
Description: these patient will have CT based customized knee instruments used for surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: these patients will have standard instrumentation used for for knee replacement
Study: NCT04056221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture stimulation was done manually, using single-use acupuncture needles that will be inserted on the selected acupoints (R6, E6, E2, Ig4, VC24, TA23, B2) once a week,for 8 weeks, 20 minutes sessions with 12 weeks of follow up.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: The sham acupuncture consists of needles that achieves no skin penetration and are holden on the points by an adhesive pad.
Study: NCT02096289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioridazine
Study: NCT00990678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocaltrol
Description: tablet, Vitamin 1-OH-D3, total 1.25-2.5 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: tablets, vitamin D3, 30 microgram daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: tablets, vitamin D3, 30 microgram daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium
Description: tablets, 400 mg calcium, 3 times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium
Description: tablets, 400 mg calcium, 3 times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: tablets, 400 mg calcium, 3 times daily
Study: NCT02637271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low calorie total meal replacement
Description: Participants will be provided instruction in the appropriate use of the meal replacement product. The participants will be directed to refrain from all items of food for a period of 21 days except for the meal replacement products and vitamin supplements provided by the investigators (1120 kcal/day). Optifast™ 800 total meal replacement shakes will be provided to the participants for the 21 day intervention period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low calorie typical diet
Description: Participants will be directed to use portion control to maintain a calorie level no greater than 1120 kcal per day. The participants will be directed to continue to consume food and beverage items that are representative of their typical diet (with the exception of reduced portions). Participants will be provided resources to assist them in determining caloric content of foods eaten.
Study: NCT04762342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power training
Description: First a brief warm up on a stationary bike and uni-lateral knee raises is completed.~Power training: Involves exercises performed with fast/explosive muscle contraction during the concentric phase, and slow/controlled (approximately 2-3 s) muscle contraction during the eccentric phase.~Functional- and balance exercises are included from week 9-24.~Progression:~Week 1-4: 3 sets of 12 repetitions at a load of 14 repetitions maximum (RM) with focus on introducing resistance exercise and familiarizing participants with exercises.~Week 5-8: 3 sets of 12 repetitions at a load of 14 RM the power training component.~Week 9-16: 3 sets of 10 repetitions at a load of 12 RM. Week 17-24: 3 sets of 8 repetitions at a load of 10 RM~Strengthening exercises:~* Bilateral leg-press~* Bilateral plantar flexion~* Bilateral knee extension~* Unilateral banded dorsal flexion~* Bilateral lying leg curl~* Back extension~* Shoulder press~* Seated row~* Chest press~* Lat pull-down
Study: NCT02973919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing Therapy
Description: In 1989, Shapiro discovered that while talking about negative life events or thoughts, rhythmic eye movements on a horizontal axis can alleviate the associated vividness and burden (Shapiro, 1989). She established the psychodynamic-behavioral Eye Movement Desensitization and Reprocessing (EMDR) Therapy, which includes the induction of rhythmic eye movements as a central feature. EMDR is regarded as an efficient treatment tool. Several times it has also been successfully applied in the field of specific phobias (de Jongh, ten Broeke, \& Renssen, 1999; de Jongh, Holmshaw, Carswell, \& van Wijk, 2011; Lapsekili \& Yelboga, 2014; Muris, Merckelbach, van Haaften, \& Mayer, 1997) and there is a standard protocol for using EMDR on specific fears and phobias (de Jongh, 2015).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Exposure Therapy
Description: Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facili- tates the practice of exposure-based treatments especially for situations or places diffi- cult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been con- ducted or only in a limited manner (Mühlberger \& Pauli, 2011).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facili- tates the practice of exposure-based treatments especially for situations or places diffi- cult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been con- ducted or only in a limited manner (Mühlberger \& Pauli, 2011).
Study: NCT02335372

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wide-Field Fluorescence Imaging
Description: Wide-field imaging in fluorescence mode performed during cervical colposcopy after topical proflavine solution applied.
Study: NCT00623922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education with individual nurse consultations
Description: 3 group meetings followed by 1-2 individual nurse consultations.
Study: NCT00232011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus Cream 1%
Description: Pimecrolimus cream 1 %
Study: NCT00679276

Intervention type: PROCEDURE
Intervention: Prolift
Description: surgical repair of vaginal prolapse
Study: NCT04954430

Intervention type: DIAGNOSTIC_TEST
Intervention: pupillometer
Description: The dynamic changes of PLR were measured using the PLR-3000 pupillometer (NeurOptics, CA, USA), a hand-held portable device. Determination of PLR with automated pupillometry can be performed with a rubber cup covering the measured eye and the subject's hand covering the non-measured eye. A flash of visible white light with a duration of 0.8 sec and a pulse intensity of 50 µW is delivered to induce a pupillary reflex, and repeated video images at more than 30 frames/sec are stored for 6.65 sec. The device provided the examiner with maximum and minimum pupil size (Init and End), constriction percentage (%PLR), latency (LAT), constriction and dilation velocity (CV and DV), and T75.
Study: NCT02205931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: The ketogenic diet is a high fat diet designed to mimic the effects on the body of starvation. The premise is the main energy intake is fat, which is utilised in the body and produces ketones.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiepileptic drug therapy
Description: The control intervention will be drug therapy with the most appropriate further antiepileptic drug for a particular child, depending on their presenting seizures and syndrome and previous drugs used, and chosen by the expert clinician responsible for management of the patient's epilepsy.
Study: NCT01597518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: 100mg BID first 24 hours after the injury; 50mg BID 2--14 days following the injury

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2x in first 24 hours; Placebo 2x day 2--14
Study: NCT01954940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Therapy